SU-DHL-4人弥漫性组织淋巴瘤细胞

价 格:¥1800

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1174

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameSU-DHL-4
SynonymsSUDHL4; Sudhl4; SUDHL-4; Sudhl-4; SuDHL 4; SUD-4; SUD4; SU4; Stanford University-Diffuse Histiocytic Lymphoma-4; DHL-4; DHL4
AccessionBTCC-1174
Resource Identification InitiativeTo cite this cell line use: SU-DHL-4 (BTCC-1174)
CommentsPart of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Population: Caucasian.
Doubling time: ~40 hours (DSMZ=ACC-495).
Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
Omics: Array-based CGH.
Omics: Cell surface proteome.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Omics: Virome analysis using RNAseq.
Derived from site: In situ; Peritoneal effusion; UBERON=UBERON_0001268.
Sequence variations
  • Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=2875799).
  • Mutation; HGNC; 3527; EZH2; Simple; p.Tyr646Ser (c.1937A>C) (Y641S); ClinVar=VCV000376218; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 3527; EZH2; Simple; p.Tyr666Asn (c.1996T>A) (Y661N); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=17363600; Cosmic-CLP; DepMap).
HLA typingSource: PubMed=26589293
Class I
HLA-AA*02:01,03:01
HLA-BB*15:01,15:01
HLA-CC*03:04,03:04

Source: DSMZCellDive=ACC-495
Class I
HLA-AA*02:01:01,02:01:01
HLA-BB*15:01:01,15:01:01
HLA-CC*03:04:01,03:04:01
Class II
HLA-DPDPA1*02:01:02,02:01:02

DPB1*01:01:01,01:01:01
HLA-DQDQA1*01:02:01,01:02:01

DQB1*06:02:01,06:02:01
HLA-DRDRA*01:02:03,01:02:03

DRB1*15:01:01,15:01:01
Genome ancestrySource: PubMed=30894373

Origin% genome


African0
Native American1.07
East Asian, North0
East Asian, South0.49
South Asian0
European, North60.53
European, South37.92
DiseaseDiffuse large B-cell lymphoma germinal center B-cell type (NCIt: C36080)
Diffuse large B-cell lymphoma (ORDO: Orphanet_544)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:

CVCL_KU32 (SU-DHL-4/12V)
Sex of cellMale
Age at sampling38Y
CategoryCancer cell line
STR profileSource(s): ATCC; Cosmic-CLP; DSMZ; PubMed=25877200

Markers:
AmelogeninX,Y
CSF1PO12
D2S133817,19
D3S135815,16
D5S81811,12
D7S8208,11
D8S117913
D13S31711,12
D16S53911,13
D18S5114,16
D19S43314
D21S1129,30
FGA19,21
Penta D9,14
Penta E7,11
TH016,9.3
TPOX9,11
vWA18,19

Run an STR similarity search on this cell line
Web pageshttps://tcpaportal.org/mclp/
Publications

PubMed=177185; DOI=10.1002/1097-0142(197605)37:5<2158::aid-cncr2820370503>3.0.CO;2-F
Epstein A.L., Herman M.M., Kim H., Dorfman R.F., Kaplan H.S.
Biology of the human malignant lymphomas. III. Intracranial heterotransplantation in the nude, athymic mouse.
Cancer 37:2158-2176(1976)

PubMed=214220; DOI=10.1002/1097-0142(197811)42:5<2379::aid-cncr2820420539>3.0.CO;2-4
Epstein A.L., Levy R., Kim H., Henle W., Henle G., Kaplan H.S.
Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines.
Cancer 42:2379-2391(1978)

PubMed=83902; DOI=10.1002/1097-0142(197901)43:1<1::aid-cncr2820430102>3.0.CO;2-M
Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.
Biology and virology of the human malignant lymphomas: 1st Milford D Schulz Lecture.
Cancer 43:1-24(1979)

PubMed=371794
Epstein A.L., Kaplan H.S.
Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines.
Cancer Res. 39:1748-1759(1979)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=3881165; DOI=10.1016/0165-4608(85)90186-4
Hecht B.K., Epstein A.L., Berger C.S., Kaplan H.S., Hecht F.
Histiocytic lymphoma cell lines: immunologic and cytogenetic studies.
Cancer Genet. Cytogenet. 14:205-218(1985)

PubMed=2875799; DOI=10.1016/0092-8674(86)90362-4
Cleary M.L., Smith S.D., Sklar J.
Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation.
Cell 47:19-28(1986)

PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x
Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Br. J. Haematol. 91:350-354(1995)

DOI=10.11418/jtca1981.15.4_211
Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.
Identification of cell lines with variable numbers of tandem repeat (VNTR) amplified by polymerase chain reaction.
Tissue Cult. Res. Commun. 15:211-219(1996)

PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x
Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N., Liu C., Kondo E., Minowada J., Akagi T.
Metastatic potential of lymphoma/leukemia cell lines in SCID mice is closely related to expression of CD44.
Jpn. J. Cancer Res. 87:1070-1077(1996)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=9787181; DOI=10.1182/blood.V92.9.3410
Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.
PTEN gene alterations in lymphoid neoplasms.
Blood 92:3410-3415(1998)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262.
Leuk. Res. 25:275-278(2001)

PubMed=12169673; DOI=10.1016/S1525-1578(10)60693-9
Robetorye R.S., Bohling S.D., Morgan J.W., Fillmore G.C., Lim M.S., Elenitoba-Johnson K.S.J.
Microarray analysis of B-cell lymphoma cell lines with the t(14;18).
J. Mol. Diagn. 4:123-136(2002)

PubMed=17363600; DOI=10.1158/0008-5472.CAN-06-3254
Strauss S.J., Higginbottom K., Juliger S., Maharaj L., Allen P., Schenkein D., Lister T.A., Joel S.P.
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Cancer Res. 67:2783-2790(2007)

PubMed=18357372; DOI=10.3892/or.19.4.889
Pop I., Pop L., Vitetta E.S., Ghetie M.-A.
Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein.
Oncol. Rep. 19:889-895(2008)

PubMed=19278952; DOI=10.1182/blood-2009-01-202028
Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T.
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Blood 113:6681-6690(2009)

PubMed=20054396; DOI=10.1038/nature08638
Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. III, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature 463:88-92(2010)

PubMed=20628145; DOI=10.1182/blood-2010-05-282780
Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R., Kutok J.L., Shipp M.A.
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Blood 116:3268-3277(2010)

PubMed=20889926; DOI=10.1182/blood-2010-06-290437
Pham L.V., Fu L., Tamayo A.T., Bueso-Ramos C., Drakos E., Vega F., Medeiros L.J., Ford R.J.
Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways.
Blood 117:200-210(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23292937; DOI=10.1073/pnas.1205299110
Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013)

PubMed=25355872; DOI=10.1128/JVI.02570-14
Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25894527; DOI=10.1371/journal.pone.0121314
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26727417; DOI=10.3109/10428194.2015.1108414
Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.
Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Leuk. Lymphoma 57:1015-1020(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28356514; DOI=10.1073/pnas.1700682114
Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M., Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L., Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017)

PubMed=29416618; DOI=10.18632/oncotarget.20378
Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S., Shen C., Young K.H., Westin J., Davis R.E., Hu S., Medeiros L.J., Ford R.J., Pham L.V.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Oncotarget 9:346-360(2018)

PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018)

PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020
Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D., Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P., Lossos I.S., Landgraf R., Vega F.
Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology.
Cancer Lett. 436:149-158(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resourcesMCCL; MCC:0000440
CCRID; 3101HUMSCSP5048
Cell_Model_Passport; SIDM00405
Cosmic-CLP; 1331035
DepMap; ACH-000365
DSMZCellDive; ACC-495
LINCS_LDP; LCL-1136
Lonza; 270
Anatomy/cell type resourcesBTO; BTO:0006462
Biological sample resourcesBioSample; SAMN03473232
BioSample; SAMN10988472
ENCODE; ENCBS265MKB
ENCODE; ENCBS980NLV
Cell line collections (Providers)ATCC; CRL-2957
CLS; 305106
DSMZ; ACC-495
ICLC; HTL10002 - Discontinued
Chemistry resourcesChEMBL-Cells; CHEMBL3308053
ChEMBL-Targets; CHEMBL613711
GDSC; 1331035
PharmacoDB; SUDHL4_1502_2019
PubChem_Cell_line; CVCL_0539
Encyclopedic resourcesWikidata; Q54970717
Experimental variables resourcesEFO; EFO_0006492

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部